share_log

Sensei Biotherapeutics Slashes Workforce, Closes R&D Site

Sensei Biotherapeutics Slashes Workforce, Closes R&D Site

Sensei 生物治療學削減勞動力，關閉研發現場
Benzinga Real-time News ·  2022/12/08 10:41
  • Sensei Biotherapeutics Inc (NASDAQ:SNSE) announced a streamlining and realignment of resources.
  • The company will close its Boston research site and reduce its workforce by approximately 40% to extend Sensei's estimated cash runway into the second half of 2025 versus Q1 of 2025 expected earlier.
  • The company will maintain its Rockville, Maryland research facility, where antibody discovery and production in support of its lead program SNS-101 and other TMAb programs is conducted while maintaining a smaller business office in the Boston area.
  • With these announcements, Robert Pierce, Sensei's Chief R&D Officer, will move to a consulting role as a Science Fellow, and Edward van der Horst, Sensei's SVP, Biologics Discovery & Early Development, has been promoted to Chief Scientific Officer.
  • Sensei continues to advance SNS-101 through investigational new drug-enabling studies and intends to submit an Investigational New Drug application (IND) in or before April 2023.
  • Price Action: SNSE shares are down 2.60% at $1.50 on the last check Thursday.
  • SENSEI生物治療公司納斯達克(Sequoia Capital：SNSE)宣佈精簡和調整資源。
  • 該公司將關閉其波士頓研究網站，並裁員約40%，以將Sensei預計的現金跑道延長至2025年下半年，而此前預計2025年第一季度。
  • 該公司將保留其位於馬利蘭州羅克維爾的研究設施，在那裡進行抗體發現和生產，以支持其領先計劃SNS-101和其他TMAb計劃，同時在波士頓地區保留一個較小的商業辦事處。
  • 宣佈這些消息後，Sensei的首席研發官羅伯特·皮爾斯將擔任科學研究員的諮詢職務，Sensei負責生物製品發現和早期開發的高級副總裁Edward van der Horst已晉升為首席科學官。
  • SENSEI繼續通過研究性新藥使能研究推進SNS-101，並打算在2023年4月或之前提交研究性新藥申請(IND)。
  • 價格行動：瑞士證券交易所股價週四收盤時下跌2.60%，至1.50美元。
声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論